Verified· 2 sources

Ageronix SA

Summary

About the company

Ageronix's core activity is the development of treatments for neurodegenerative diseases, particularly using the protein Alpha 1 Anti-Trypsin (AAT). The company focuses on researching and developing therapies for rare neurological disorders, such as Charcot-Marie-Tooth disease (CMT), and has already completed preclinical developments and plans to initiate clinical trials in 2024.

AI-generated

Offering

Products & services

Industry:Pharmaceutical Industry

✓ Offered3

Development of therapies for neurological diseases

Preclinical and clinical development of alpha-1 antitrypsin–based therapies for neurological diseases, in particular Charcot-Marie-Tooth disease.

Research on alpha-1 antitrypsin therapies

Research into the therapeutic use of alpha-1 antitrypsin, including human and recombinant AAT for inflammatory and neurodegenerative diseases.

Development of therapies for Charcot-Marie-Tooth disease

Development of a new treatment candidate for Charcot-Marie-Tooth disease, including preclinical development, FDA Orphan Drug Designation, and clinical trial phase.

Outbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub

Ageronix SA

About the company

Products & services

Looking for direct email addresses and phone numbers?

Ageronix SA

About the company

Products & services

Looking for direct email addresses and phone numbers?

No knowledge articles yet

Ageronix SA in comparison

Industry comparisons are coming soon

Similar companies